Sultan Quraishi, MD
General Practice · East Hartford, CTNPI 1144200122
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 455 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 35.2% of the total. Reporting peaked in 2022 at $1,399 and has fallen 58.8% since, to $576 in 2025. Among general practice clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 455 payments — averaging $13.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$907
- GSK$392
- Pfizer$285
- AstraZeneca$244
- Novo Nordisk$237
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,964100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 231 | $2,106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 58 | $907 |
| GSK | 36 | $392 |
| Pfizer | 16 | $285 |
| AstraZeneca | 12 | $244 |
| Novo Nordisk | 13 | $237 |
| Phathom Pharmaceuticals, Inc. | 7 | $186 |
| Ironwood Pharmaceuticals, Inc | 8 | $184 |
| Lilly USA, LLC | 8 | $179 |
| Ardelyx, Inc. | 8 | $154 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $124 |
| Genentech USA, Inc. | 6 | $120 |
| Arbor Pharmaceuticals, Inc. | 6 | $102 |
| Biohaven Pharmaceuticals, Inc. | 3 | $68 |
| Amgen(2 entities) | 4 | $67 |
| Merck | 4 | $57 |
| Eisai Inc. | 3 | $53 |
| Johnson & Johnson | 3 | $47 |
| Boehringer Ingelheim | 2 | $47 |
| Amarin Pharma, Inc. | 2 | $44 |
| Abbott | 2 | $38 |
| Novartis | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $22 |
| Optinose US, Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
How this compares
$5,979 in reported general payments places this provider in the 95th percentile of 1,190 general practice providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 69 | $88,093 |
| JardianceEmpagliflozin | 52 | $77,604 |
| JanumetSitagliptin Phos/Metformin Hcl | 48 | $76,414 |
| JanuviaSitagliptin Phosphate | 49 | $68,041 |
| RybelsusSemaglutide | 15 | $35,852 |
| XareltoRivaroxaban | 23 | $31,272 |
| FarxigaDapagliflozin Propanediol | 18 | $24,162 |
| TradjentaLinagliptin | 12 | $18,305 |
| EliquisApixaban | 13 | $18,267 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $17,246 |
| OzempicSemaglutide | 11 | $17,201 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $11,175 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $6,521 |
| Lidocaine | 30 | $4,327 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia, Janumet Xr | $57 | $155,630110 claims |
| Boehringer IngelheimJardiance, Tradjenta | $47 | $95,90964 claims |
| AbbVieLinzess | $2,106 | $88,09369 claims |
| Novo NordiskRybelsus, Ozempic | $237 | $53,05226 claims |
| Johnson & JohnsonXarelto | $47 | $31,27223 claims |
| AstraZenecaFarxiga, Symbicort | $244 | $28,15132 claims |
| PfizerEliquis | $285 | $18,26713 claims |
| GSKTrelegy Ellipta | $392 | $17,24623 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $22 | $1,27116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,190 general practice providers in Connecticut.
Other general practice in East Hartford
- Elizabeth BoigEast Hartford$3K
- Vincent RaucciNorth Haven$268K
- Jeffrey HoosStratford$113K
- James CrossHartford$73K
- David FantarellaNorth Haven$33K
- David EdelsonPlainville$29K
- Yousong WangNew Britain$23K
- Michael YoungWindsor$16K
- Julia LathamStratford$13K
- Lawrence ChristianSimsbury$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.